v3.25.2
Other Operating Income and Expenses (Tables)
 12 Months Ended
Mar. 31, 2025
Analysis of income and expense [abstract]  
Schedule of Other Operating Income and Expenses
JPY (millions)
For the Year Ended March 31
202320242025
Other operating income:
Change in fair value of financial assets and liabilities associated with contingent consideration arrangements (Note 27)¥— ¥— ¥2,390 
Gain on sales of property, plant and equipment and investment property2,094 144 363 
Gain on divestment of business to Teva Takeda Yakuhin6,807 588 4,117 
Gain on divestment of business and subsidiaries (Note 19)
— 7,243 6,081 
Change in estimate of liabilities related to SHP6474,102 — — 
Other12,421 11,404 13,262 
Total¥25,424 ¥19,379 ¥26,212 
Other operating expenses:
Donations and contributions¥7,685 ¥7,009 ¥7,663 
Restructuring expenses (Note 23)59,234 81,358 128,133 
Change in fair value of financial assets and liabilities associated with contingent consideration arrangements (Note 27)3,991 20,757 1,788 
Valuation reserve for pre-launch inventories (reversal)
9,466 11,052 (7,313)
Impairment of assets held for sale (Note 19)4,693 1,685 6,812 
Other60,178 84,666 69,650 
Total¥145,247 ¥206,527 ¥206,733